Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Expanding Ampyra's Reach? Studies In Other Neurological Conditions Have Stumbled, But Acorda Has Not Ruled Out Future Development

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The fampridine molecule has been used as a pharmacy compounded product for a variety of neurological conditions based on its mechanism of action. In animal studies, the drug "has been shown to increase conduction of nerve signals in demyelinated axons through blocking of potassium channels," Acorda observed in its annual 10-K filing on Feb. 26.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts